Endra Life Sciences announced the launch of the Nexus 128+, adding to their preclinical photoacoustic computed tomography (CT) systems that leverage ENDRA's proprietary 3D imaging technology.
"The Nexus 128+ now provides up to twice the photoacoustic sensitivity of our previous system, the Nexus 128, enabling improved quantitation of preclinical animal models," said Michael Thornton, ENDRA's Chief Technology Officer. ENDRA's preclinical photoacoustic CT scanners are used by global research scientists to quantify molecular probe uptake and tumor vasculature.
ENDRA will showcase the Nexus 128+ at the 2016 World Molecular Imaging Congress (WMIC) in New York, NY, September 7 – 10, 2016, Booth #513.
The company will also highlight recent studies, including an application note that demonstrates dual probe, 4D imaging to quantify molecular probe tumor penetration.
"The launch of the Nexus 128+ demonstrates ENDRA's ongoing commitment to developing leading-edge tools that enable researchers to study disease models with unparalleled quality and speed," said Francois Michelon, ENDRA's Chief Executive Officer.
ENDRA Life Science's mission is to bring new capabilities to ultrasound.
ENDRA's Photoacoustic solutions currently help global medical researchers screen and modify disease models with high image quality and volume scanning speed.
ENDRA has a global installed base of leading institutions using the Nexus 128 system, the only fully 3D photoacoustic imaging solution for imaging anatomy, physiology and labeled molecular targets.